Avila scientists find new opportunities for covalent drugs

4 April 2011

Privately-held US biotech firm Avila Therapeutics announced the publication of a scientific review article in Nature Reviews Drug Discovery, titled The Resurgence of Covalent Drugs ( www.nature.com/reviews/drugdisc, Vol 10, April 2011, Singh, J), which discusses the broad opportunities for covalent drugs and how structural bioinformatics coupled with structure-based drug design can enable the design of highly selective covalent drugs with unique therapeutic properties for treating diseases.

Avila recently announced an $800 million deal - $40 million up front - with French drug major Sanofi-Aventis to develop drug candidates for cancer targets using the US firm’s proprietary technology for covalent drugs (The Pharma Letter December 20, 2010).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >